Upstream Processing Industry News

1. Biologics Research Promises To Bolster Future Of Medicine 3/11/2013

   America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

2. Baxter Initiates Phase I Clinical Trial With Anti-MIF Antibody In Patients With Solid Tumors 9/5/2012

   Baxter International Inc. has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company’s efforts to extend its oncology portfolio with advanced biological research and development.

3. Sirnaomics Received NIH SBIR Grant For Developing Its Scarless Wound Healing siRNA Therapeutics 6/25/2012

   Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.

4. Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 3/29/2012
   New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
5. Argen-X Launches NHance™ Technology To Generate Better Human Antibody Therapies 3/20/2012
   arGEN-X announces today the launch of NHance™, its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics.
6. Roche´s MagNA Pure LC 2.0 System For Monitoring DNA In Therapeutic Proteins And Monoclonal Antibody Drugs 3/1/2012
   To ensure product safety, clearance of host-cell DNA is essential when manufacturing therapeutic proteins and monoclonal antibody (mAB) drugs.
7. Waters And NIBRT Complete Work On World's First UPLC Glycan Database 1/23/2012
   Waters Corporation (WAT:NYSE) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT) announced today the availability of the world's first database for glycan analysis by UltraPerformance Liquid Chromatography® (UPLC®).
8. Xencor Receives U.S. Patent For Monoclonal Antibody Engineering That Extends Duration Of Action 1/11/2012
   Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.
9. Vermillion Completes The Acquisition Of Correlogic Systems' Ovarian Cancer Diagnostics Business 12/19/2011
   Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has completed the purchase of substantially all of the assets associated with the ovarian cancer diagnostics business of Correlogic Systems, Inc. for $435,000 in cash.
10. Single-Use Bioreactors For Pharma: World Market 2011-2021 7/19/2011
    How will the market for single-use bioreactors develop this decade? Our new report shows you that emerging market's revenue potential from 2011 to 2021, discussing its prospects.